Envoy Medical (COCH) Common Equity (2021 - 2026)
Envoy Medical's Common Equity history spans 6 years, with the latest figure at $10.2 million for Q1 2026.
- On a quarterly basis, Common Equity rose 141.95% to $10.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $10.2 million, a 141.95% increase, with the full-year FY2025 number at -$12.2 million, up 35.47% from a year prior.
- Common Equity hit $10.2 million in Q1 2026 for Envoy Medical, up from -$12.2 million in the prior quarter.
- Over the last five years, Common Equity for COCH hit a ceiling of $10.2 million in Q1 2026 and a floor of -$47.5 million in Q1 2023.
- Historically, Common Equity has averaged -$19.1 million across 5 years, with a median of -$18.8 million in 2024.
- Biggest five-year swings in Common Equity: tumbled 960.92% in 2024 and later skyrocketed 141.95% in 2026.
- Tracing COCH's Common Equity over 5 years: stood at -$36.2 million in 2022, then surged by 95.09% to -$1.8 million in 2023, then tumbled by 960.92% to -$18.8 million in 2024, then soared by 35.47% to -$12.2 million in 2025, then soared by 183.57% to $10.2 million in 2026.
- Business Quant data shows Common Equity for COCH at $10.2 million in Q1 2026, -$12.2 million in Q4 2025, and -$7.7 million in Q3 2025.